GLPwatch
Semaglutide
Approved · GLP-1 receptor agonist
Last updated 2026-09-22Semaglutide is a medication that mimics a natural hormone called GLP-1, which helps control blood sugar and appetite. It is sold under the brand names Ozempic, Wegovy, and Rybelsus, and is FDA-approved to treat type 2 diabetes, obesity, chronic kidney disease, and to reduce cardiovascular risk.
AI summary of the sources below.
| Mechanism | GLP-1 receptor agonist Mimics GLP-1, a gut hormone that raises insulin, lowers blood sugar, and reduces appetite. |
|---|---|
| Status | Approved |
| Branded products | ozempic, wegovy, rybelsus |
| Manufacturer(s) | novo-nordisk |
How Semaglutide connects
- Products OzempicRybelsusWegovy
- Treats Type 2 diabetesCardiovascular risk reductionChronic kidney diseaseObesity
- Maker Novo Nordisk
- Trials 470 trials
- Research 2,323 papers
Trials (470)
- Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
- A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
- 16-week Flexible vs. 8-week Semaglutide Titration
- The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
- A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).
- A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity
- Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
- Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
- Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
- Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
- Bariatric Surgery vs. Semaglutide vs. Tirzepatide
- DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
- A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
- A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- Semaglutide in Nonalcoholic Fatty Liver Disease
- A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- Semaglutide and Cognition in Healthy Volunteers
- Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
- A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
- Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
- SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
- A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
- A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
- A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
Top research (2323)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
- The Discovery and Development of Liraglutide and Semaglutide.
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
- Semaglutide lowers body weight in rodents via distributed neural pathways.
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.